Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00612274
Other study ID # 0703002455
Secondary ID
Status Completed
Phase Phase 0
First received January 29, 2008
Last updated November 29, 2016
Start date October 2007
Est. completion date October 2014

Study information

Verified date November 2016
Source Yale University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose format of 5mg/m2 on days +1,3 and 6 only.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Patients must have an identified 8/10 or 9/10 matched unrelated donor identified following a formal search with confirmatory typing through the national marrow donor program as the best available donor. No matched sibling or fully matched unrelated donor has been identified. HLA typing of donor and recipient will be performed by high resolution molecular typing at HLA A, B, C and DRB1/DQ loci. Patients whose best available donor is matched at 8/10 loci must have at least one of the mismatches at the DQ locus. (no more than one mismatch at HLA A,B,C,DR allowed).

- Candidates for this trial will meet the following criteria:

1. Adequate organ function for conditioning type:

For patients receiving ablative conditioning

- Left Ventricular ejection fraction >45%

- DLCO >50%

- Creatinine <1.5

- Hepatic enzymes <3x upper limit of normal.

- KPS >70%

For patients receiving non-ablative conditioning:

- KPS >70%

2. Patients with the following diseases will be considered eligible:

- AML in first remission with high risk features (poor risk cytogenetic abnormalities9, persistent elevated blast count on day +15 or recovery marrow after induction therapy).

- AML beyond first remission

- ALL in first remission with high risk features (ph+, t4:11)

- ALL beyond first remission

- High risk Myelodysplasia (RAEB-II, RAEB-I with poor-risk cytogenetics)

- Recurrent Aggressive Non-Hodgkins or Hodgkins lymphoma (indolent histologies excluded) who have failed autologous transplant or have had inadequate response to salvage therapy.

- CML with transformation

- CLL with transformation or Fludarabine failure.

- Severe aplastic anemia with recurrence or failure after immunosuppressive therapy.

Exclusion Criteria:

- Prior allogeneic transplantation

- Active CNS leukemia.

- Female patients who are pregnant or breast feeding

- Karnofsky performance status <70%.

- Active viral, bacterial or fungal infection.

- Patients seropositive for HIV -1,2; HTLV -1,2 (due to the additional immunodeficiency induced by transplantation and immunosuppressive therapy) Requirement for antifungal prophylaxis with Voriconazole for the first 30 days is prohibited.

- Patients not providing informed consent.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
tacrolimus
Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
Sirolimus
Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
Methotrexate
Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.

Locations

Country Name City State
United States Yale University School of Medicine New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety/Efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate Upon completion of study Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03918343 - Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation N/A
Not yet recruiting NCT05438823 - Technology Supported Education Program Based on Human Care Theory N/A
Not yet recruiting NCT02193399 - Physiotherapy in Hematopoietic Stem Cell Transplantation N/A
Withdrawn NCT00972101 - Infusion of Expanded Cord Blood T Cells Phase 1
Completed NCT05421299 - A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
Completed NCT04976933 - Post-HSCT Medication Adherence mHealth App
Completed NCT04798495 - Feasibility of a Rehabilitation Programme Targeted Patients Treated With Non-myeloablative Stem Cell Transplantation N/A
Active, not recruiting NCT04511130 - Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Phase 2
Recruiting NCT05968963 - Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation N/A
Recruiting NCT02940093 - Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers N/A
Not yet recruiting NCT06077734 - Muscle Stem Cell Quality in Atrophy
Terminated NCT00587990 - Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) Phase 1/Phase 2
Terminated NCT00597441 - Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation Phase 1
Active, not recruiting NCT03684083 - Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients
Recruiting NCT00884338 - Cognitive Function After Stem Cell Transplantation Phase 3
Completed NCT00284713 - Progenitor Cell Therapy in Dilative Cardiomyopathy Phase 1/Phase 2
Withdrawn NCT00062543 - Hepatic Artery Infusion of CD34+ Cells Phase 1
Completed NCT00781170 - Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma Phase 2
Recruiting NCT03364257 - iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients
Enrolling by invitation NCT06134297 - Adherence, Viability, Clinical Evolution and Therapeutic Efficacy in Patients Undergoing Bone Marrow Transplantation N/A